|
Kidney Cancer – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 284 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Kidney Cancer - Pipeline Review, H1 2012', provides an overview of the Kidney Cancer therapeutic pipeline. This report provides information on the therapeutic d.....
Introduction Global Markets Direct’s, 'Kidney Cancer - Pipeline Review, H1 2012', provides an overview of the Kidney Cancer therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. 'Kidney Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Kidney Cancer. - A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Cancer pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Kidney Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Kidney Cancer therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Kidney Cancer Overview 12 Therapeutics Development 13 An Overview of Pipeline Products for Kidney Cancer 13 Kidney Cancer Therapeutics under Development by Companies 15 Kidney Cancer Therapeutics under Investigation by Universities/Institutes 23 Late Stage Products 35 Comparative Analysis 35 Mid Clinical Stage Products 36 Comparative Analysis 36 Early Clinical Stage Products 37 Comparative Analysis 37 Discovery and Pre-Clinical Stage Products 38 Comparative Analysis 38 Kidney Cancer Therapeutics – Products under Development by Companies 39 Kidney Cancer Therapeutics – Products under Investigation by Universities/Institutes 48 Companies Involved in Kidney Cancer Therapeutics Development 75 Bristol-Myers Squibb Company 75 Genzyme Corporation 76 Boehringer Ingelheim GmbH 77 F. Hoffmann-La Roche Ltd. 78 Kyowa Hakko Kirin Co., Ltd. 79 Amgen Inc. 80 AstraZeneca PLC 81 Eli Lilly and Company 82 GlaxoSmithKline plc 83 Seattle Genetics, Inc. 84 Genentech, Inc. 85 Merck & Co., Inc. 86 Emergent BioSolutions Inc. 87 Oxford BioMedica plc 88 Light Sciences Oncology, Inc. 89 Novartis AG 90 ImClone Systems Incorporated 91 Astellas Pharma Inc. 92 Eisai Co., Ltd. 93 Ono Pharmaceutical Co., Ltd. 94 OSI Pharmaceuticals, Inc. 95 Pfizer Inc. 96 Taiho Pharmaceutical Co., Ltd. 97 Exelixis, Inc. 98 Alfacell Corporation 99 Celgene Corporation 100 Bayer AG 101 MannKind Corporation 102 3SBio Inc. 103 EntreMed, Inc. 104 Celldex Therapeutics, Inc. 105 Active Biotech AB 106 AEterna Zentaris Inc. 107 AIDA Pharmaceuticals, Inc. 108 Lorus Therapeutics Inc 109 Bionomics Limited 110 Northwest Biotherapeutics, Inc. 111 Cleveland BioLabs, Inc. 112 Patrys Limited 113 Keryx Biopharmaceuticals, Inc. 114 ARQULE, INC 115 Allos Therapeutics, Inc 116 Flamel Technologies S.A. 117 Dendreon Corporation 118 Green Cross Corporation 119 MOLOGEN AG 120 OncoTherapy Science, Inc. 121 Threshold Pharmaceuticals, Inc. 122 Innate Pharma SA 123 Protox Therapeutics Inc. 124 Rexahn Pharmaceuticals, Inc. 125 Debiopharm Group 126 Antisense Pharma GmbH 127 Wilex AG 128 Philogen S.p.A. 129 Cadila Pharmaceuticals Ltd. 130 ERYtech Pharma 131 immatics biotechnologies GmbH 132 Curacyte AG 133 Argos Therapeutics, Inc. 134 Cytheris SA 135 Altor BioScience Corporation 136 AgrenVec, S.L. 137 Alethia Biotherapeutics Inc. 138 Gene Signal International SA. 139 MacroGenics, Inc. 140 Pivotal BioSciences, Inc. 141 Neotropix, Inc. 142 Jennerex Biotherapeutics, Inc. 143 Endocyte, Inc. 144 Advenchen Laboratories, LLC 145 Immutep S.A. 146 Syndax Pharmaceuticals, Inc. 147 Esperance Pharmaceuticals, Inc. 148 Welichem Biotech Inc. 149 Tigris Pharmaceuticals, Inc. 150 AVEO Pharmaceuticals, Inc. 151 KAHR medical Ltd. 152 Advanced Cancer Therapeutics 153 Medical Enzymes AG 154 IkerChem S.L. 155 Immunovative Therapies, Ltd. 156 Kidney Cancer – Therapeutics Assessment 157 Assessment by Monotherapy Products 157 Assessment by Combination Products 158 Assessment by Route of Administration 159 Assessment by Molecule Type 162 Drug Profiles 165 Nexavar - Drug Profile 165 Axitinib - Drug Profile 167 Axitinib - Drug Profile 169 Sutent - Drug Profile 171 ANYARA - Drug Profile 173 IMA901 - Drug Profile 174 TroVax - Drug Profile 175 NuLeusin - Drug Profile 177 Tivozanib - Drug Profile 178 Rencarex - Drug Profile 180 Dovitinib - Drug Profile 182 Aldesleukin for Kidney Cancer - Drug Profile 184 Aldesleukin + Recombinant interferon alfa + Fluorouracil - Drug Profile 185 Bevacizumab + Torisel - Drug Profile 187 Gemcitabine + Cisplatin + Bevacizumab - Drug Profile 188 Interferon Alfa-2B + Bevacizumab - Drug Profile 189 Interferon Alfa-2B - Drug Profile 190 BAY43-9006 - Drug Profile 191 Sunitinib - Drug Profile 193 Dactinomycin + Doxorubicin + Vincristine - Drug Profile 194 Sorafenib Tosylate - Drug Profile 195 Recombinant Interferon Alfa + Isotretinoin - Drug Profile 196 Interferon Alfa + CCI-779 - Drug Profile 197 BCG Vaccine + Iressa - Drug Profile 198 Interleukin-2 - Drug Profile 199 Dactinomycin + Filgrastim + Cylophosphamide + Doxorubicin hydrochloride + Etoposide + Vincristine sulfate + Radiation therapy - Drug Profile 200 RAD001 - Drug Profile 203 TroVax + IL-2 - Drug Profile 205 Interferon-Alpha + Interleukin-2 + 5-Fluorouracil - Drug Profile 207 Filgrastim + Doxorubicin + Ifosfamide - Drug Profile 209 Interferon-Alpha - Drug Profile 211 Votrient - Drug Profile 212 Everolimus + Bevacizumab - Drug Profile 214 ANYARA + Interferon Alpha - Drug Profile 215 Sunitinib - Drug Profile 216 Interferon-alpha - Drug Profile 217 Interleukin 2 + Interferon-alpha2 - Drug Profile 218 Dactinomycine + Doxorubicin + Vincristine + Radiation Therapy - Drug Profile 219 Sorafenib - Drug Profile 220 Sorafenib + Sunitinib - Drug Profile 221 bevacizumab + recombinant interferon alfa - Drug Profile 222 Carboplatin + Methotrexate + Vinblastine - Drug Profile 223 aldesleukin + recombinant interferon alfa + fluorouracil - Drug Profile 225 Dactinomycin + Carboplatin + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Vincristine Sulfate - Drug Profile 227 Doxorubicin hydrochloride - Drug Profile 230 Gemcitabine + Cisplatin - Drug Profile 231 Sunitinib - Drug Profile 233 Recombinant Gamma Interferon - Drug Profile 234 Cisplatin + Radiation Therapy - Drug Profile 235 Sunitinib - Drug Profile 236 Bevacizumab + Interferon Alfa-2a - Drug Profile 237 Kidney Cancer Therapeutics – Drug Profile Updates 238 Kidney Cancer Therapeutics – Discontinued Products 245 Kidney Cancer Therapeutics - Dormant Products 249 Kidney Cancer – Product Development Milestones 270 Featured News & Press Releases 270 Appendix 279 Methodology 279 Expert Panel Validation 280 Contact Us 280 Disclaimer 280 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Kidney Cancer, H1 2012 17 Products under Development for Kidney Cancer – Comparative Analysis, H1 2012 18 Number of Products under Development by Companies, H1 2012 20 Number of Products under Development by Companies, H1 2012 (Contd..1) 21 Number of Products under Development by Companies, H1 2012 (Contd..2) 22 Number of Products under Development by Companies, H1 2012 (Contd..3) 23 Number of Products under Development by Companies, H1 2012 (Contd..4) 24 Number of Products under Development by Companies, H1 2012 (Contd..5) 25 Number of Products under Development by Companies, H1 2012 (Contd..6) 26 Number of Products under Investigation by Universities/Institutes, H1 2012 28 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 29 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 30 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 31 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 32 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 33 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 34 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 35 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 36 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 37 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 38 Comparative Analysis by Late Stage Development, H1 2012 39 Comparative Analysis by Mid Clinical Stage Development, H1 2012 40 Comparative Analysis by Early Clinical Stage Development, H1 2012 41 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 42 Products under Development by Companies, H1 2012 43 Products under Development by Companies, H1 2012 (Contd..1) 44 Products under Development by Companies, H1 2012 (Contd..2) 45 Products under Development by Companies, H1 2012 (Contd..3) 46 Products under Development by Companies, H1 2012 (Contd..4) 47 Products under Development by Companies, H1 2012 (Contd..5) 48 Products under Development by Companies, H1 2012 (Contd..6) 49 Products under Development by Companies, H1 2012 (Contd..7) 50 Products under Development by Companies, H1 2012 (Contd..8) 51 Products under Investigation by Universities/Institutes, H1 2012 52 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 53 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 54 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 55 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 56 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 57 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 58 Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 59 Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 60 Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 61 Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 62 Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 63 Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 64 Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 65 Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 66 Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 67 Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 68 Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 69 Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 70 Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 71 Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 72 Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 73 Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 74 Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 75 Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 76 Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 77 Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 78 Bristol-Myers Squibb Company, H1 2012 79 Genzyme Corporation, H1 2012 80 Boehringer Ingelheim GmbH, H1 2012 81 F. Hoffmann-La Roche Ltd., H1 2012 82 Kyowa Hakko Kirin Co., Ltd., H1 2012 83 Amgen Inc., H1 2012 84 AstraZeneca PLC, H1 2012 85 Eli Lilly and Company, H1 2012 86 GlaxoSmithKline plc, H1 2012 87 Seattle Genetics, Inc., H1 2012 88 Genentech, Inc., H1 2012 89 Merck & Co., Inc., H1 2012 90 Emergent BioSolutions Inc., H1 2012 91 Oxford BioMedica plc, H1 2012 92 Light Sciences Oncology, Inc., H1 2012 93 Novartis AG, H1 2012 94 ImClone Systems Incorporated, H1 2012 95 Astellas Pharma Inc., H1 2012 96 Eisai Co., Ltd., H1 2012 97 Ono Pharmaceutical Co., Ltd., H1 2012 98 OSI Pharmaceuticals, Inc., H1 2012 99 Pfizer Inc., H1 2012 100 Taiho Pharmaceutical Co., Ltd., H1 2012 101 Exelixis, Inc., H1 2012 102 Alfacell Corporation, H1 2012 103 Celgene Corporation, H1 2012 104 Bayer AG, H1 2012 105 MannKind Corporation, H1 2012 106 3SBio Inc., H1 2012 107 EntreMed, Inc., H1 2012 108 Celldex Therapeutics, Inc., H1 2012 109 Active Biotech AB, H1 2012 110 AEterna Zentaris Inc., H1 2012 111 AIDA Pharmaceuticals, Inc., H1 2012 112 Lorus Therapeutics Inc, H1 2012 113 Bionomics Limited, H1 2012 114 Northwest Biotherapeutics, Inc., H1 2012 115 Cleveland BioLabs, Inc., H1 2012 116 Patrys Limited, H1 2012 117 Keryx Biopharmaceuticals, Inc., H1 2012 118 ARQULE, INC, H1 2012 119 Allos Therapeutics, Inc, H1 2012 120 Flamel Technologies S.A., H1 2012 121 Dendreon Corporation, H1 2012 122 Green Cross Corporation, H1 2012 123 MOLOGEN AG, H1 2012 124 OncoTherapy Science, Inc., H1 2012 125 Threshold Pharmaceuticals, Inc., H1 2012 126 Innate Pharma SA, H1 2012 127 Protox Therapeutics Inc., H1 2012 128 Rexahn Pharmaceuticals, Inc., H1 2012 129 Debiopharm Group, H1 2012 130 Antisense Pharma GmbH, H1 2012 131 Wilex AG, H1 2012 132 Philogen S.p.A., H1 2012 133 Cadila Pharmaceuticals Ltd., H1 2012 134 ERYtech Pharma, H1 2012 135 immatics biotechnologies GmbH, H1 2012 136 Curacyte AG, H1 2012 137 Argos Therapeutics, Inc., H1 2012 138 Cytheris SA, H1 2012 139 Altor BioScience Corporation, H1 2012 140 AgrenVec, S.L., H1 2012 141 Alethia Biotherapeutics Inc., H1 2012 142 Gene Signal International SA., H1 2012 143 MacroGenics, Inc., H1 2012 144 Pivotal BioSciences, Inc., H1 2012 145 Neotropix, Inc., H1 2012 146 Jennerex Biotherapeutics, Inc., H1 2012 147 Endocyte, Inc., H1 2012 148 Advenchen Laboratories, LLC, H1 2012 149 Immutep S.A., H1 2012 150 Syndax Pharmaceuticals, Inc., H1 2012 151 Esperance Pharmaceuticals, Inc., H1 2012 152 Welichem Biotech Inc., H1 2012 153 Tigris Pharmaceuticals, Inc., H1 2012 154 AVEO Pharmaceuticals, Inc., H1 2012 155 KAHR medical Ltd., H1 2012 156 Advanced Cancer Therapeutics, H1 2012 157 Medical Enzymes AG, H1 2012 158 IkerChem S.L., H1 2012 159 Immunovative Therapies, Ltd., H1 2012 160 Assessment by Monotherapy Products, H1 2012 161 Assessment by Combination Products, H1 2012 162 Assessment by Stage and Route of Administration, H1 2012 165 Assessment by Molecule Type, H1 2012 168 Kidney Cancer Therapeutics – Drug Profile Updates 242 Kidney Cancer Therapeutics – Discontinued Products 249 Kidney Cancer Therapeutics – Discontinued Products (Contd..1) 250 Kidney Cancer Therapeutics – Discontinued Products (Contd..2) 251 Kidney Cancer Therapeutics – Discontinued Products (Contd..3) 252 Kidney Cancer Therapeutics – Dormant Products 253 Kidney Cancer Therapeutics – Dormant Products (Contd..1) 254 Kidney Cancer Therapeutics – Dormant Products (Contd..2) 255 Kidney Cancer Therapeutics – Dormant Products (Contd..3) 256 Kidney Cancer Therapeutics – Dormant Products (Contd..4) 257 Kidney Cancer Therapeutics – Dormant Products (Contd..5) 258 Kidney Cancer Therapeutics – Dormant Products (Contd..6) 259 Kidney Cancer Therapeutics – Dormant Products (Contd..7) 260 Kidney Cancer Therapeutics – Dormant Products (Contd..8) 261 Kidney Cancer Therapeutics – Dormant Products (Contd..9) 262 Kidney Cancer Therapeutics – Dormant Products (Contd..10) 263 Kidney Cancer Therapeutics – Dormant Products (Contd..11) 264 Kidney Cancer Therapeutics – Dormant Products (Contd..12) 265 Kidney Cancer Therapeutics – Dormant Products (Contd..13) 266 Kidney Cancer Therapeutics – Dormant Products (Contd..14) 267 Kidney Cancer Therapeutics – Dormant Products (Contd..15) 268 Kidney Cancer Therapeutics – Dormant Products (Contd..16) 269 Kidney Cancer Therapeutics – Dormant Products (Contd..17) 270 Kidney Cancer Therapeutics – Dormant Products (Contd..18) 271 Kidney Cancer Therapeutics – Dormant Products (Contd..19) 272 Kidney Cancer Therapeutics – Dormant Products (Contd..20) 273 List of Figures Number of Products under Development for Kidney Cancer, H1 2012 17 Products under Development for Kidney Cancer – Comparative Analysis, H1 2012 18 Products under Development by Companies, H1 2012 19 Products under Investigation by Universities/Institutes, H1 2012 27 Late Stage Products, H1 2012 39 Mid Clinical Stage Products, H1 2012 40 Early Clinical Stage Products, H1 2012 41 Discovery and Pre-Clinical Stage Products, H1 2012 42 Assessment by Monotherapy Products, H1 2012 161 Assessment by Combination Products, H1 2012 162 Assessment by Route of Administration, H1 2012 163 Assessment by Stage and Route of Administration, H1 2012 164 Assessment by Molecule Type, H1 2012 166 Assessment by Stage and Molecule Type, H1 2012 167 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
